tradingkey.logo
tradingkey.logo
Search

Biohaven Ltd

BHVN
Add to Watchlist
13.500USD
-0.330-2.39%
Close 07-31 16:00ETQuotes delayed by 15 min
2.03BMarket Cap
LossP/E TTM

Biohaven Ltd

13.500
-0.330-2.39%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.39%

5 Days

-5.73%

1 Month

-14.34%

6 Months

+14.12%

Year to Date

+19.57%

1 Year

-8.23%

Key Figures
13.870Open
13.940High
1.43MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.95%Turnover Ratio
13.820Prev. Close
13.253Low
9.36MTurnover
LossP/E Static
15.69P/B
0.00%Div Yield TTM
-139.99%ROA
18.56652wk High
0.74Volume Ratio
-846.42MNet Profit
150.51MShares
-5.5746EPS TTM
3.29Beta
-333.00%ROE
7.48052wk Low
4.97%Amplitude
--Gross Margin
2.03BMarket Cap
-2.90Reward/Risk
4.78%Risk Rate

Biohaven Ltd News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 17 analysts
Buy
Current Rating
23.571
Target Price
+74.60%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Biohaven Ltd
BHVN
17
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(2)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.648
Neutral
RSI(14)
44.046
Neutral
STOCH(KDJ)(9,3,3)
17.771
Oversold
ATR(14)
0.846
High Vlolatility
CCI(14)
-124.869
Sell
Williams %R
86.090
Oversold
TRIX(12,20)
-0.017
Sell
StochRSI(14)
13.864
Oversold
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
13.806
Sell
MA10
14.312
Sell
MA20
14.914
Sell
MA50
13.371
Buy
MA100
11.434
Buy
MA200
11.585
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Biohaven Ltd Info

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
Ticker SymbolBHVN
CompanyBiohaven Ltd
CEOCoric (Vlad)
Websitehttps://www.biohaven.com/

Shareholders

Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.16%
Suvretta Capital Management, LLC
6.83%
1919 Investment Counsel, LLC
6.59%
Childs John W
6.56%
BlackRock Institutional Trust Company, N.A.
5.15%
Other
63.70%

FAQs

What is the current price of Biohaven Ltd (BHVN)?

The current price of Biohaven Ltd (BHVN) is 13.50.

What is the symbol of Biohaven Ltd?

The ticker symbol of Biohaven Ltd is BHVN.

What is the 52-week high of Biohaven Ltd?

The 52-week high of Biohaven Ltd is 18.57.

What is the 52-week low of Biohaven Ltd?

The 52-week low of Biohaven Ltd is 7.48.

What is the market capitalization of Biohaven Ltd?

The market capitalization of Biohaven Ltd is 2.03B.

Is Biohaven Ltd (BHVN) currently rated as Buy, Hold, or Sell?

According to analysts, Biohaven Ltd (BHVN) has an overall rating of Buy, with a price target of 23.21.

What is the Earnings Per Share (EPS TTM) of Biohaven Ltd (BHVN)?

The Earnings Per Share (EPS TTM) of Biohaven Ltd (BHVN) is -6.86.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.